Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 3,079 shares, an increase of 51.5% from the December 31st total of 2,033 shares. Based on an average daily volume of 10,514 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the shares of the company are short sold. Currently, 0.3% of the shares of the company are short sold. Based on an average daily volume of 10,514 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several institutional investors have recently made changes to their positions in GNOM. Flow Traders U.S. LLC grew its stake in shares of Global X Genomics & Biotechnology ETF by 52.4% in the second quarter. Flow Traders U.S. LLC now owns 238,725 shares of the company’s stock valued at $2,012,000 after buying an additional 82,063 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares during the period. Oppenheimer Asset Management Inc. increased its position in shares of Global X Genomics & Biotechnology ETF by 8.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock worth $756,000 after buying an additional 6,708 shares during the period. Insight Advisors LLC PA boosted its stake in Global X Genomics & Biotechnology ETF by 47.9% during the second quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock worth $503,000 after acquiring an additional 19,319 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Global X Genomics & Biotechnology ETF by 110.4% in the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after purchasing an additional 12,105 shares in the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM stock traded up $0.24 during trading hours on Monday, reaching $47.93. 5,307 shares of the company’s stock were exchanged, compared to its average volume of 9,691. The company’s 50 day moving average is $47.21 and its two-hundred day moving average is $41.95. Global X Genomics & Biotechnology ETF has a 1 year low of $27.20 and a 1 year high of $51.42. The company has a market cap of $52.24 million, a P/E ratio of -20.48 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Dividend Announcement

The firm also recently announced a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were paid a dividend of $0.5912 per share. The ex-dividend date was Tuesday, December 30th. This represents a yield of 259.0%. Global X Genomics & Biotechnology ETF’s payout ratio is presently -26.50%.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.